Trial Profile
A retrospective, observational, cohort study to evaluate treatment patterns and outcomes in patients with metastatic Non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology